Washington,
D.C. 20549
FORM
6-K
REPORT
OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of November 2005
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level
12
BGC Centre
28
The
Esplanade
Perth
WA
6000
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form
20-F
ý Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
ý
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
|
pSivida
Limited
|
||
| |
|
|
| Date: November 16, 2005 | By: | /s/ Aaron Finlay |
|
Aaron Finlay |
||
| Chief Financial Officer and Company Secretary | ||
EXHIBIT
INDEX
|
EXHIBIT
99.1:
|
pSivida
recognized in Small Times Magazine’s Best of Small Tech
Awards
|
-2-
|
ASX/Media
RELEASE
|
 |
16
November 2005
pSivida
recognized in the Small Times Magazine
Best
of Small Tech Awards
Global
bio-nanotech company pSivida Limited (ASX:PSD,
NASDAQ:PSDV, Xetra:PSI)
is
pleased to announce that it has been recognised as a runner-up in the Best
of
Small Tech Awards ‘Company of the Year’ category. The
fourth annual Small Times Magazine Best of Small Tech Awards highlights the
top
leaders and the biggest successes in nanotechnology during the past
year.
pSivida
Managing Director, Mr Gavin Rezos said, “We are very honoured to be recognised
in these prestigious awards. This award clearly demonstrates pSivida’s
leadership position in the emerging global bio-nanotech industry”.
Nominees
for the ‘Company of the Year’ are evaluated by Small Times Media staff and seven
panels of industry experts. Awards are based on accomplishments between 1
September 2004 and 1 September 2005. Further information on these Awards
is
available online at www.smalltimes.com.
Small
Times Magazine is a leading source of business news and analysis about the
small
tech industry. Circulation is free to qualified subscribers around the world
in
both print and digital form. In addition to its news services (Small Times
magazine, SmallTimes.com, Small Times Direct, Small Tech Advantage), Small
Times
organises the leading nanotechnology business conference and trade show in
North
America, NanoCommerce.
pSivida
held its AGM yesterday in Sydney, Australia at which its shareholders
demonstrated strong endorsement of the acquisition of Control Delivery Systems
(CDS), a Boston based drug delivery company. The acquisition is now
unconditional and we look forward to welcoming the shareholders of CDS as
shareholders of pSivida.
-ENDS-
Released
by:
|
pSivida
Limited
Brian
Leedman
Investor
Relations
pSivida
Limited
Tel:
+ 61 8 9226 5099
brianl@psivida.com
|
US
Public Relations
Beverley
Jedynak
President
Martin
E. Janis & Company, Inc
Tel:
+1 (312) 9 1100 ext. 12
bjedynak@janispr.com
|
UK
& Europe Public Relations
Mark
Swallow / Helena Podd
Citigate
Dewe Rogerson
Tel:
+44 (0)20 7638 9571
mark.swallow@citigatedr.co.uk
|
NOTES
TO EDITORS:
pSivida
is a global bio-nanotech company committed to the biomedical sector and the
development of products in healthcare. The company’s focus is the development
and commercialisation of a modified form of silicon (porosified or
nano-structured silicon) known as BioSilicon™.
pSivida
owns the intellectual property pertaining to BioSilicon™ for use in or on humans
and animals. The IP portfolio consists of 29 patent families, 34 granted
patents
and over 80 patent applications. The core patent, which recognises BioSilicon™
as a biomaterial was granted in the UK in 2000 and in the US in 2001.
pSivida
is listed on NASDAQ (PSDV),
the Australian Stock Exchange (PSD)
and in Germany on the Frankfurt Stock Exchange on the XETRA system (German Symbol:
PSI. Securities Code (WKN) 358705).
pSivida’s shares also trade in the United Kingdom on the OFEX International
Market Service (IMS) under the ticker symbol PSD.
pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
Lynch Nanotechnology Index.
The
Company's strategic partner and largest shareholder is QinetiQ, a leading
international defence, security and technology company, formed in July 2001
from
the UK Government's Defence Evaluation & Research Agency (DERA).
QinetiQ was instrumental in discovering BioSilicon(TM) and pSivida enjoys
a
strong relationship with it having access to its cutting edge research and
development facilities. For more information on QinetiQ visit
www.QinetiQ.com
For
more
information, visit www.psivida.com
This
document contains forward-looking statements that involve risks and
uncertainties. Although we believe that the expectations reflected in such
forward-looking statements are reasonable at this time, we can give no assurance
that such expectations will prove to be correct. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Actual results could differ materially from those anticipated
in
these forward-looking statements due to many important factors including:
our
failure to develop applications for BioSiliconTM
due to
regulatory, scientific or other issues. Other reasons are contained in
cautionary statements in the Registration Statement on Form 20-F filed with
the
U.S. Securities and Exchange Commission, including, without limitation, under
Item 3.D, "Risk Factors" therein. We do not undertake to update any
oral or
written forward-looking statements that may be made by or on behalf of
pSivida.